Skip to main content
. 2022 Dec 14;6:e2200457. doi: 10.1200/PO.22.00457

FIG 1.

FIG 1.

Comparing the survival of patients on the basis of high/low PD-L1 expression after treatment (T1). (A) PFS of ICI patients with high PD-L1 expression (solid blue) v ICI patients with low PD-L1 expression (solid red). Median PFS 4.8 v 17 months. PFS of no ICI patients with high PD-L1 expression (dotted blue) v no ICI patients with low PD-L1 expression (dotted red). Median PFS 8.1 v 9.6 months. (B) OS of ICI patients with high PD-L1 expression (solid blue) v ICI patients with low PD-L1 expression (solid red). Median OS 5.9 v 21 months. OS of no ICI patients with high PD-L1 expression (dotted blue) v no ICI patients with low PD-L1 expression (dotted red). Median OS 9.9 v 16 months. ICI, immune checkpoint inhibitor; OS, overall survival; PD-L1, programmed death 1 receptor and its ligand; PFS, progression-free survival.